Patent · US Active

Method for designing a drug regime for HIV-infected patients

US8338101B2 · kind B2 · utility

0Cited by

2References

1Claims

0Family size

Assignee

Virco BVBA · BE

Inventors

Kurt Van Baelen · Westerlo, BE
Lieven Stuyver · Borsbeke, BE
Kevin Karel Florentina Arien · Antwerpen, BE

Key dates

Filing date	Jan 23, 2008
Grant date	Dec 25, 2012
Priority date	—
Expiry date	Feb 21, 2029

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/10
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.